Clinical Trial: A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT06954246) titled 'A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer' on April 18.

Brief Summary: This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).

Study Start Date: May, 2025

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer Extensive Stage

Intervention: DRUG: MHB088C for Injection

2 mg/kg intravenous dose on Day 1 and Day 15 of each 28-day cycle

DRUG: Topotecan

1.25 mg/m^2 intravenous dose on Day 1 to Day 5 of each 21-day cycle

D...